Full Press Release Details
PHARMACEUTICALS LTD.
OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Be Held on February 11, 2020
Annual General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the "Company") will be held at the offices
of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli Center, Tel Aviv 6701101, Israel on February
11, 2020 at 4:00 p.m. Israel time, or at any adjournments thereof (the "General Meeting") for the following purposes:
addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements
of the Company for the fiscal years ended December 31, 2018.
Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly
raised at the General Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.
holders of record of ordinary shares, no par value (the "Ordinary Shares"), and holders of record of ADSs, evidenced
by American Depositary Receipts issued by The Bank of New York Mellon at the close of business on January 6, 2019 shall be entitled
to receive notice of and to vote at the General Meeting (the "Record Date").
The Board of Directors
recommends that you vote FOR each of the proposals.
Whether or not you plan to attend the
General Meeting, it is important that your Ordinary Shares be represented. Accordingly, you are kindly requested to complete, date,
sign and mail the proxy to be provided separately at your earliest convenience. Execution of a proxy will not in any way affect
a shareholder's right to attend the General Meeting and vote in person, and any person giving a proxy has the right to revoke
it at any time before it is exercised.
holders should return their proxies by the date set forth on their form of proxy.
either registered in the Company's shareholders' register in Israel or
who hold Ordinary Shares through members of the Tel Aviv Stock Exchange, and who intend to vote their Ordinary Shares either in
person or by proxy, must deliver to the Company's offices, c/o Mr. Uri Ben Or, Chief Financial Officer, at BiondVax Pharmaceuticals
Ltd., Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, no later than February 11, 2020, at
10:00 a.m. Israel time, an ownership certificate confirming their ownership of the Company's Ordinary Shares on the Record
Date, which certificate must be issued or approved by a recognized financial institution, as required by the Israeli Companies
Regulations (Proof of Ownership of Shares for Voting at General Meeting) of 2000, as amended. Shareholders either
registered in the Company's shareholders' register in Israel or who hold Ordinary Shares through members of
the Tel Aviv Stock Exchange may vote through the attached proxy by completing, dating, signing and mailing the proxy to the Company's
offices, c/o Mr. Uri Ben Or at BiondVax Pharmaceuticals Ltd., Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem
9112001, Israel, so that it is received by the Company no later than February 7, 2020, at 4:00 p.m. Israel time.
wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement ("Position
Statement") to the Company's offices, c/o Mr. Uri Ben Or at at BiondVax Pharmaceuticals Ltd., Jerusalem BioPark, 2nd
Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, by no later than February 3, 2020. Any Position Statement received
that is in accordance with the guidelines set by the Companies Law will be furnished to the U.S. Securities and Exchange Commission
(the "Commission") on Form 6-K, and will be made available to the public on the Commission's website at http://www.sec.gov.
no legal quorum be present one-half hour after the scheduled time, the General Meeting will be adjourned to one week from that
day, at the same time and place, i.e. on February 18, 2020, at 4:00 p.m. (Israel Time) at the offices of Gross, Kleinhendler,
Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli Center, Tel Aviv 6701101, Israel. Should such legal quorum not be present
half an hour after the time set for the adjourned meeting, any number of shareholders present, in person or by proxy, will constitute
This Notice and the documents
mentioned therein, as well as the proposed resolutions on the agenda, will be made available at the Company's registered office
on Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, Tel: +972-(8)-930-2529, Sunday through
Thursday between 10:00-15:00, and also will be made available to the public on the Company's website http://www.biondvax.com,
the Commission's website at http://www.sec.gov.
| By Order of the Board of Directors, | |
| Mark Germain | |
| Chairman of the Board of Directors |